MEA115666: A Multi-centre, Open-label, Long Term Safety Study of Mepolizumab in Asthmatic Subjects Who Participated in the MEA112997 Trial
Latest Information Update: 03 Jul 2023
At a glance
- Drugs Mepolizumab (Primary)
- Indications Asthma
- Focus Adverse reactions; Registrational
- Acronyms COLUMBA
- Sponsors GlaxoSmithKline; GSK
- 22 Oct 2018 Results published in the Journal of Allergy and Clinical Immunology
- 23 May 2018 Results assessing the durability of Clinical Response, presented at the 114th International Conference of the American Thoracic Society
- 23 May 2018 Long-term safety results presented at the 114th International Conference of the American Thoracic Society